CT-guided high-dose-rate interstitial brachytherapy for malignant lung lesions in a resource-limited setting
Brachytherapy · 2026
DOI: 10.1016/j.brachy.2025.09.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Simit Sapkota und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Kathmandu Cancer Center, Bhaktapur 44800, Nepal. Hauptthemen laut MEDLINE: Brachytherapy, Lung Neoplasms, Tomography, X-Ray Computed, Radiotherapy, Image-Guided. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Several nonsurgical techniques are available for the management of inoperable primary and metastatic lung diseases. While Stereotactic body radiotherapy is a well-established technique, its access in low and middle-income countries (LMICs) is restricted. This study aims to present our experience on the feasibility of the high-dose-rate interstitial brachytherapy (IBT) in inoperable lung lesions, including technique and outcomes in LMICs. MATERIALS AND METHODS: Eleven patients/12 primary and metastatic lung lesions were treated with the IBT at a single cancer center between June 2022 and June 2024. The patients were treated by a multidisciplinary team comprising intervention radiologists, radiation oncologists, and medical oncologists. Treatment response was assessed using RECIST version 1.1. RESULTS: The study cohort included 6 males and 5 females with a median age of 55 years (range, 39-75). The median volume of the lesions treated was 8.1 cc (range, 1.7-30.8). All the lesions were treated with a 20 Gy dose. The best response included complete responses in 6, partial responses in 1, stable disease in 4 and progressive disease in 1 lesion treated. The local control was 75 % for a median follow-up of 18.7 months (range, 8.3-35.9). Patients experienced no major procedural complications except self-limiting minor pneumothorax (27.3%), hemoptysis (27.3%) and fever (18.2%). CONCLUSIONS: Our findings present the CT-guided IBT as an effective, safe, and minimally invasive treatment approach for patients with primary or metastatic lung lesions who pose challenges for surgery, with a good local control rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology, Kathmandu Cancer Center, Bhaktapur 44800, Nepal.
- Department of Clinical Oncology, Kathmandu Cancer Center, Bhaktapur 44800, Nepal. Electronic address: dr.subhas@kccrc.org.
- Department of Radiology, Kathmandu Cancer Center, Bhaktapur, Nepal.
- Department of Research and Academics, Kathmandu Cancer Center, Bhaktapur, Nepal.
- Department of Radiation Oncology, Kathmandu Cancer Center, Bhaktapur, Nepal.
- Department of Medical Oncology, Kathmandu Cancer Center, Bhaktapur, Nepal.
Zitieren
APA
Sapkota, S., Pandit, S., Suwal, S., Bhandari, J., Adhikari, A., Prajapati, R., Prasai, G., Shrestha, S., & Jha, A. K. (2026). CT-guided high-dose-rate interstitial brachytherapy for malignant lung lesions in a resource-limited setting. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.09.015
Vancouver
Sapkota S, Pandit S, Suwal S, Bhandari J, Adhikari A, Prajapati R, et al. CT-guided high-dose-rate interstitial brachytherapy for malignant lung lesions in a resource-limited setting. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.09.015
BibTeX
@article{Sapkota2026,
author = {Sapkota, Simit and Pandit, Subhas and Suwal, Sundar and Bhandari, Jeebana and Adhikari, Abish and Prajapati, Rajan and Prasai, Gerim and Shrestha, Sunil and Jha, Anjani Kumar},
title = {CT-guided high-dose-rate interstitial brachytherapy for malignant lung lesions in a resource-limited setting},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2025.09.015}
}
EUVIMED